Loading...

EMMAUS LIFE SCIENCES INC Company Mergers 8-K Filing

MMS

EMMAUS LIFE SCIENCES INC

()

2026 8-K

Financial Results Announced

Director Appointment

Director Resignation

Financial Results Released

Supply Agreement Update

License Agreement Signed

Stock Exchange Agreement

Director Resignation

Financial Update

Financial Results Announced

Financial Statements

Appointing Accounting Firm

Financial Results

External Links:

On March 2, 2026, Emmaus Life Sciences, Inc. entered into an Exclusive Supply Agreement with NeoImmuneTech, following a previous License Agreement from December 24, 2025. This agreement stipulates that Emmaus will supply its product, Endari®, exclusively to NeoImmuneTech at a price based on their production costs plus a specified margin.

AI Assistant

EMMAUS LIFE SCIENCES INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.